APA

Roux C., Hofbauer L. C., Ho P. R., Wark J. D., Zillikens M. C., Fahrleitner-Pammer A., Hawkins F., Micaelo M., Minisola S., Papaioannou N., Stone M., Ferreira I., Siddhanti S., Wagman R. B. & Brown J. P. (20140831). Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. : Bone.

Chicago

Roux C, Hofbauer L C, Ho P R, Wark J D, Zillikens M C, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman R B and Brown J P. 20140831. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. : Bone.

Harvard

Roux C., Hofbauer L. C., Ho P. R., Wark J. D., Zillikens M. C., Fahrleitner-Pammer A., Hawkins F., Micaelo M., Minisola S., Papaioannou N., Stone M., Ferreira I., Siddhanti S., Wagman R. B. and Brown J. P. (20140831). Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. : Bone.

MLA

Roux C, Hofbauer L C, Ho P R, Wark J D, Zillikens M C, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman R B and Brown J P. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. : Bone. 20140831.